Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Lancet Oncol. 2018 Sep 17;19(10):1351–1359. doi: 10.1016/S1470-2045(18)30487-X

Table 4:

Dosing and Reasons for Treatment Discontinuation

Number of Patients (%)
Total Evaluable 31 (100)
800mg 13 (42)
600mg 12 (39)
400mg 6 (19)
Reason off therapy 32 (100)
Transaminitis 4 (13)
Other toxicities 3 (10)
Progression 6 (20)
Patient choice 11 (35)
Ongoing treatment 7 (32)
Death 1 (3)